These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 35579580)

  • 1. Clinical observations regarding the use of androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer.
    Oh WK
    Clin Adv Hematol Oncol; 2022 May; 20 Suppl 9(5):13-16. PubMed ID: 35579580
    [No Abstract]   [Full Text] [Related]  

  • 2. How patient characteristics can guide selection among androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer.
    Rettig MB
    Clin Adv Hematol Oncol; 2022 May; 20 Suppl 9(5):9-12. PubMed ID: 35579579
    [No Abstract]   [Full Text] [Related]  

  • 3. Factors that guide selection among androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer: Q&A.
    Oh WK; Rettig MB
    Clin Adv Hematol Oncol; 2022 May; 20 Suppl 9(5):16-17. PubMed ID: 35579581
    [No Abstract]   [Full Text] [Related]  

  • 4. Recent clinical trial data of androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer.
    Beltran H
    Clin Adv Hematol Oncol; 2022 May; 20 Suppl 9(5):2-8. PubMed ID: 35579578
    [No Abstract]   [Full Text] [Related]  

  • 5. How quality of life can help guide selection of androgen receptor inhibitors in nonmetastatic castration-resistant prostate cancer.
    Smith MR
    Clin Adv Hematol Oncol; 2021 Oct; 19(10):627-630. PubMed ID: 34637427
    [No Abstract]   [Full Text] [Related]  

  • 6. Cases in the management of nonmetastatic castration-resistant prostate cancer: darolutamide as the first androgen receptor inhibitor in a fit, older man.
    Lowentritt BH
    Clin Adv Hematol Oncol; 2022 Jan; 20 Suppl 1(1):1-8. PubMed ID: 35343943
    [No Abstract]   [Full Text] [Related]  

  • 7. Safety differences across androgen receptor inhibitors in nonmetastatic castration-resistant prostate cancer.
    Shore N; Garcia-Horton V; Terasawa E; Ayyagari R; Grossman JP; Waldeck AR
    Future Oncol; 2023 Feb; 19(5):385-395. PubMed ID: 36794575
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination Therapy with Androgen Receptor Pathway Inhibitors for Prostate Cancer.
    Blas L; Shiota M
    Curr Cancer Drug Targets; 2023; 23(6):428-432. PubMed ID: 36803751
    [No Abstract]   [Full Text] [Related]  

  • 9. Dual therapy in metastatic castration-resistant prostate cancer.
    Huang J; Leng F
    Lancet Oncol; 2024 Jul; 25(7):e283. PubMed ID: 38936382
    [No Abstract]   [Full Text] [Related]  

  • 10. Enzalutamide for the treatment of nonmetastatic castration-resistant prostate cancer.
    Altavilla A; Casadei C; Lolli C; Menna C; Ravaglia G; Gurioli G; Farolfi A; Brighi N; Conteduca V; Burgio SL; Schepisi G; Rossi L; Gargiulo S; Lisotti I; De Giorgi U
    Expert Opin Pharmacother; 2020 Dec; 21(17):2091-2099. PubMed ID: 32783772
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The biology of castration-resistant prostate cancer.
    Lian F; Sharma NV; Moran JD; Moreno CS
    Curr Probl Cancer; 2015; 39(1):17-28. PubMed ID: 25547388
    [No Abstract]   [Full Text] [Related]  

  • 12. Bone health effects of androgen-deprivation therapy and androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer.
    Hussain A; Tripathi A; Pieczonka C; Cope D; McNatty A; Logothetis C; Guise T
    Prostate Cancer Prostatic Dis; 2021 Jun; 24(2):290-300. PubMed ID: 33028943
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [ASC-J9 for castration-resistant prostate cancer].
    Yamashita S; Arai Y
    Nihon Rinsho; 2014 Dec; 72(12):2126-9. PubMed ID: 25518345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors that guide selection among androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer.
    Rettig MB; Beltran H; Oh WK
    Clin Adv Hematol Oncol; 2022 May; 20 Suppl 9(5):1-20. PubMed ID: 35579577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Galeterone activity in castration-resistant prostate cancer.
    Yaqub F
    Lancet Oncol; 2015 Jan; 16(1):e10. PubMed ID: 25638544
    [No Abstract]   [Full Text] [Related]  

  • 16. Utility of novel androgen receptor therapies in the real world: A nuanced approach.
    Dhawan M; Ryan CJ
    Urol Oncol; 2016 Aug; 34(8):340-7. PubMed ID: 27450893
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Survival outcomes in older men with non-metastatic castration-resistant prostate cancer treated with androgen receptor inhibitors: a US Food and Drug Administration pooled analysis of patient-level data from three randomised trials.
    Fallah J; Zhang L; Amatya A; Gong Y; King-Kallimanis B; Bhatnagar V; Weinstock C; Suzman DL; Agrawal S; Chang E; Anscher MS; Chi DC; Xu JX; Brewer JR; Brave MH; Hadadi M; Theoret MR; Kluetz PG; Goldberg KB; Ibrahim A; Tang S; Pazdur R; Beaver JA; Amiri-Kordestani L; Singh H
    Lancet Oncol; 2021 Sep; 22(9):1230-1239. PubMed ID: 34310904
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resistance to Hormonal Therapy in Prostate Cancer.
    Berruti A; Dalla Volta A
    Handb Exp Pharmacol; 2018; 249():181-194. PubMed ID: 28353036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Leading causes of castration-resistant prostate cancer.
    Lu M; Lu H; Kong Q
    Expert Rev Anticancer Ther; 2015 Apr; 15(4):425-32. PubMed ID: 25645203
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I and II therapies targeting the androgen receptor for the treatment of castration resistant prostate cancer.
    Dellis A; Papatsoris AG
    Expert Opin Investig Drugs; 2016 Jun; 25(6):697-707. PubMed ID: 26954621
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.